Long-Term Debt: MiNK (INKT)

Brandmark of MiNK Therapeutics, Inc (INKT)

MiNK Therapeutics, Inc. (INKT) develops universal iNKT therapies capable of destroying tumors and suppressing inflammation without the risk of rejection. The quotes provided below demonstrate a long-term debt structure, which stands at 0.00. The business relies on the serial production of donor cells to reduce labor costs; however, a critical dependence on test results and a liquidity deficit necessitate strict capital management.

INKT (MiNK) Company Long-Term Debt history from 07/04/2022 to 11/01/2026

MiNK - analytical breakdowns and key metrics (INKT)

- current quotes and average value forecast:
Stock Quotes minktherapeutics.com|INKT - Price Target Chart
- company stock exchange capitalization indicators:
Market Value MiNK Therapeutics|INKT - Total Company Value
- book capitalization data:
Net Assets per Single Share MiNK Therapeutics|INKT - Company Book Value|Market-to-Book Ratio minktherapeutics.com|INKT - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio MiNK Therapeutics, Inc.|INKT - Long-Term Debt to Equity Ratio|Current Liabilities to Capital MiNK Therapeutics, Inc|INKT - Company Total Debt|Debt to Net Assets Ratio MiNK Therapeutics|INKT - Company Long-Term Debts|Short-Term Debt Volume MiNK Therapeutics|Quick Liquidity Indicator minktherapeutics.com
- net income and valuation multiples indicators:
INKT - Company Net Income
Fundamental company valuation:minktherapeutics.com
Core merchandise of MiNK Therapeutics

Long-term debt measures the total amount of credit obligations with a maturity of more than one year, where load stability protects against default but may limit the growth rate of capitalization. Monitoring the issuer's long-term liabilities allows for an assessment of the financial stability of MiNK Therapeutics, Inc. (INKT) given its high dependence on external contract sites necessary for the uninterrupted production of cell products and laboratory audits.

Who MiNK Therapeutics, Inc. competes with

IBRX - Company Long-Term Liabilities|IMCR - Company Long-Term Debt|Long-Term Debt Janux Therapeutics Inc|Arcus Bio (RCUS) - Company Long-Term Debt|ZYME (Zymeworks Biopharmaceuticals) - Company Long-Term Debt|Company Long-Term Debt Tango Therapeutics|Long-Term Debt iovance.com IOVA|Company Long-Term Debts IMTX|Xencor Inc (XNCR) - Long-Term Indebtedness|Compass Bio - Company Long-Term Liabilities|Replimune Inc. (REPL) - Long-Term Debt|LYEL: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Long-Term Debts|CGEN - Long-Term Debt Volume|Company Long-Term Debt IO Biotech Corp|Company Long-Term Liabilities Sutro Biopharma, Inc (STRO)|Company Long-Term Debt Werewolf Therapeutics (HOWL)|Company Long-Term Liabilities immixbio.com IMMX|ALX Oncology Holdings - Company Long-Term Liabilities|Company Long-Term Debts cuebiopharma.com CUE|PDSB - Company Long-Term Debt|SONN (Sonnet BioTherapeutics) - Company Long-Term Indebtedness|MAIA Biotechnology (MAIA) - Company Long-Term Debt|Long-Term Debt liminatuspharma.com (LIMN)|Company Long-Term Liabilities LVTX|NXTC - Long-Term Indebtedness|Company Long-Term Liabilities LPTX (Leap Therapeutics, Inc.)|Amount of Long-Term Liabilities INTS|Company Long-Term Debts SNSE (Sensei Biotherapeutics, Inc.)|Company Long-Term Loans and Borrowings TOVX|Gritstone Bio - Company Long-Term Debts|Long-Term Debt Kineta Inc|NexImmune Corp (NEXI) - Company Long-Term Debt|Turnstone Biologics Corp. - Company Long-Term Loans and Borrowings|VCNX (Vaccinex, Inc.) - Company Long-Term Debts|Company Long-Term Debts harpoontx.com